Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

© @DFID_Press

Professor Feiko ter Kuile, an expert in malaria in pregnancy, recently worked with a multi-disciplinary team including the US Centers for Disease Control and Prevention, the WorldWide Antimalarial Resistance Network (WWARN) and Duke University to complete the most comprehensive study to date of the impact of sulphadoxine-pyrimethamine (SP) drug resistance on the effectiveness of intermittent preventative treatment (IPTp).

Published in Lancet Infectious Diseases, the results demonstrate that the clinical effectiveness of SP in protection of pregnant women against malaria is compromised in certain areas. The experts call for further urgent investigation into alternative strategies or drugs to prepare for further growing resistance to this mainstay of preventive therapy.

The WHO recommends intermittent preventive treatment (IPTp) in malaria endemic areas. The only antimalarial currently recommended for IPTp is SP; to date IPTp with SP has effectively resulted in reductions in maternal anaemia, low birth weight and neonatal mortality. However, with the growing threat of drug resistance emerging or spreading in sub-Saharan Africa, this protection is now at risk.

It is estimated that without protection during pregnancy, 45% of 32 million pregnancies in malaria endemic sub-Saharan Africa are exposed to Plasmodium falciparum malaria, leading to 900,000 malaria-associated low birthweight deliveries. Low birth weight, anaemia and other serious adverse birth outcomes result in numerous longer-term health issues for infants.

Prof ter Kuile from LSTM comments, “We reviewed more than 100,000 birth outcomes across Sub-Saharan Africa, our results suggest that the widely used antimalarial SP for preventive therapy remains very effective in many parts of Africa, but that there is a clear trend toward reduced effectiveness with increasing levels of resistance by the malaria parasite to SP. In areas with the highest grade of resistance where more than 37% of parasites carry six mutations in the so-called pfdhfr and pfdhps genes, the effectiveness of SP appears to be fully compromised. It is clear that in these high resistance settings alternative approaches to the prevention of malaria in pregnancy are urgently needed to achieve better birth outcomes for pregnant women.”

Carol Sibley, WWARN’s Senior Scientific Advisor from the University of Washington, adds, “This large-scale analysis has given us a powerful message: the increasing prevalence of molecular markers of SP is correlated with a decrease in effectiveness of SP to reduce low birth weight and malaria infections.

We also have a clear recommendation that molecular monitoring of parasites in humans is a valuable tool for policy makers to monitor the spread of antimalarial resistance and assess the impact on this valuable prevention strategy for malaria in pregnancy and therewith on the lives of newborns in low income settings across Africa.”

Since resistance evolves by a series of mutations in the parasite, molecular monitoring of parasites in humans can support policy makers and health professionals to make important decisions about the need for alternative prevention options.

Anna Maria van Eijk, first author concludes, “We are also calling for further analysis into the potential additional benefits that SP may continue to have even in areas where it is no longer able to kill malaria parasites. For example, through its anti-microbial effects, or perhaps SP has some anti-inflammatory and immune modulating effects that are similar to those discovered for widely used antibiotic cotrimoxazole. This is important as SP may not work as well as other antimalarials in high SP resistance areas, but it may still be able to help reduce poor birth outcomes, such as low birth weight through these other mechanisms.

We hope that by examining the risks, outcomes and alternative strategies available we will ensure that vulnerable babies born in low resource settings are given the best possible chance of good health, by receiving the most effective antimalarial prevention approaches and medicines available to us today, and in the future.”

Anna Maria van Eijk et al. Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. Lancet Infectious Diseases. Online March 25, 2019.

Find out more here: Malaria Epidemiology Department, LSTM and MiP Consortium

Liverpool School of Tropical Medicine (LSTM)is the world's oldest centre of excellence in tropical medicine and international public health. It has been engaged in the fight against infectious, debilitating and disabling diseases since 1898 and continues that tradition today with a research portfolio ​over £320 million and a teaching programme attracting students from over 65 countries.

The WorldWide Antimalarial Research Network (WWARN)'s mission is to generate innovative tools and reliable evidence to inform the malaria community on the factors affecting the efficacy of antimalarial medicines. WWARN works with collaborators to optimise the efficacy of antimalarial medicines and treatment regimens, especially for vulnerable groups including pregnant women, infants and malnourished children, and provides evidence to inform the development of new antimalarial drugs. 

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.